3Loftsson T. Cyclodextrins in Pharmaceutical Formulations [M]. Nordic Industrial Fund, 1998.2-34.
4Karel D B, Jef V G. Pharmacology of itraconazole[J]. Drugs, 2001,61(Suppl 1):27.
5Ponec R J, Hackman R C, McDonald G B. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation[J]. Gastrointest Endose, 1999,49(5):612.
6De Doncker P, Decroix J, Pierard G E, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole[J]. Arch Dermatol, 1996, 132(1):34.
7Cross L J, Bagg J, Aitchison T C. Efficacy of the cyclodextrin liquid preparation of itraconazole in treatment of denture stomatitis: comparison with itraconazole capsules[J]. Antimicrob Agents Chemother, 2000,44(2):425.
8Barone J A, Moskovitz B L, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers[J]. Antimicrob Agents Chemother, 1998,42(7):1862.
9Stevens D A. Itraconazole in cyclodextrin solution[J]. Pharmacotherapy, 1999,19(5):603.
10Prentice H G, Caillot D, Dupont B, et al. Oral and intravenous itraconazole for systemic fungal infection in neutropenic haematological patients: meeting report[J]. Acta Haematol, 1999,101(1):56.
